Circulating levels of specific members of chromosome 19 microRNA cluster are associated with preeclampsia development

Abstract

Serum hsa-miRs 512-3p, 518f-3p, 520c-3p, and 520d-3p, are differentially expressed between WWD-PE and controls and their role in the development of preeclampsia should be investigated further.

Publication-based analysis of miR-210 dependent biomarkers of pre-eclampsia

“…Of these miRNAs, one miRNA (519d) in studies without miR-210 Yang et al, 2011;Li et al, 2013;Yang et al, 2015) and three (517c, 518b, 518e) in all studies Guo et al, 2011;Mayor-Lynn et al, 2011;Yang et al, 2011;Ishibashi et al, 2012;Li et al, 2013;Ura et al, 2014;Xu et al, 2014;Yang et al, 2015;Vashukova et al, 2016) were mapped to the C19MC cluster, the largest human miRNA gene cluster, whose expression is almost exclusively confined to the placenta. The cluster spans ~100 kb on chromosome 19q13.41 and contains 54 predicted miRNA genes, 43 of which have been cloned and sequenced (Poirier et al, 2017).…”

“…in the direction of miR-518b expression change. In the context of miR-210 differential expression, miR-518b is upregulated in PE Ura et al, 2014;Xu et al, 2014) while it has decreased expression in studies where miR-210 levels are unchanged (Guo et al, 2011;Mayor-Lynn et al, 2011). This fact is important for understanding possible mechanisms of PE development, especially in early pregnancy terms when miR-518b is already detected in the plasma, as it can be used for routine screening of pregnant women according to changed miRNA expression profiles.…”

“…In most studies miR-223 is significantly downregulated in PE placentas Choi et al, 2013;Xu et al, 2014;Vashukova et al, 2016;) and blood (Yang et al, 2011;Li et al, 2013). Only in two studies without miR-210, miR-223 was upregulated in the placenta (Guo et al, 2011;Mayor-Lynn et al, 2011). The expression of miR-223 is regulated by several transcriptional factors, such as CCAAT-enhancer-binding proteins (C/EBP)-α and -ß and nuclear factor I-A (NFI-A) (Kapinas and Delany, 2011).…”

“…Further studies have shown that miRNA-223 is involved in osteoclastogenesis (NF-IA), granulopoiesis (IKKα, NF-IA, E2F), erythropoiesis (LMO2), cell invasiveness (MEF2C), tumor suppression (EPB4IL3), tumorigenesis (STMN1, FBW7, KRAS, EGF, EGFR2, MMP9, SEPTIN6), inflammation (NLRP3, Pknox1), glucose uptake (GLUT-4), VSMC proliferation (IGF-1R), and VSMC contractile phenotype (Rho B, MEF2C), which are associated with oncology, type 2 diabetes, cardiovascular diseases and diseases of the musculoskeletal system (Taïbi et al, 2014). There have also been studies where miR-223 is differentially expressed in various pregnancy complications, with the exception of PE, such as preterm birth (Mayor-Lynn et al, 2011;Tang et al, 2015;Enquobahrie et al, 2016;Gray et al, 2017;Winger et al, 2017;Menon et al, 2019).…”

“…Moreover, increased levels of miR-210 were detected in plasma samples before clinical manifestations of PE. However, miR-210 is not reported as a marker of PE in about half of the studies using both blood and placenta samples (Guo et al, 2009;Mayor-Lynn et al, 2011;Noack et al, 2011;Yang et al, 2011;Wang et al, 2012;Wu et al, 2012;Choi et al, 2013;Li et al, 2013;Akehurst et al, 2015;Yang et al, 2015;Sandrim et al, 2016;Gunel et al, 2017;Pei-Yin et al, 2017;Xu et al, 2017;Lykoudi et al, 2018;Martinez-Fierro et al, 2018;Timofeeva et al, 2018;Yoffe et al, 2018), so there is no clear understanding of regulatory pathways associated with miRNA-210 in PE.…”